Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Ralph Alvarez acquired 13 shares of Eli Lilly common stock through a deferral plan, at a price of $906.13 per share.

Summary

• Ralph Alvarez, a director at Eli Lilly & Co, acquired 13 shares of common stock on October 21, 2024.
• The shares were acquired at a price of $906.13 each.
• These shares were obtained through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock after Mr. Alvarez's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally neutral to positive. The director's acquisition of shares can be seen as a sign of confidence.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among publicly traded companies, including pharmaceutical companies like Pfizer (PFE) and Johnson & Johnson (JNJ).
• These plans are often used to align the interests of directors with those of shareholders.
• The specific terms of deferral plans can vary, but the general concept of deferring compensation into company stock is widely used.

Stakeholder Impact

• The acquisition of shares by a director can be seen positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Eli Lilly, LLY, Director, Share Acquisition, Deferral Plan, Form 4, Insider Trading